• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.

作者信息

Chilukuri Dakshina, McMaster Owen, Bergman Kimberly, Colangelo Philip, Snow Kerry, Toerner Joseph G

机构信息

Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.

Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.

出版信息

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.

DOI:10.1093/cid/civ460
PMID:26224770
Abstract
摘要

相似文献

1
The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.抗结核药物治疗方案非临床评价中的中空纤维系统模型
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.
2
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.中空纤维系统模型在结核病中的应用：欧洲药品管理局的经验。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S1-4. doi: 10.1093/cid/civ484.
3
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.系统分析结核病实验中空纤维模型。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425.
4
Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.在感染结核分枝杆菌的豚鼠中使用纳米颗粒包裹的抗结核药物进行口服治疗。
Antimicrob Agents Chemother. 2005 Oct;49(10):4335-8. doi: 10.1128/AAC.49.10.4335-4338.2005.
5
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.中空纤维模型预测结核病临床治疗结局的准确性。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S25-31. doi: 10.1093/cid/civ427.
6
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.唑类抗真菌药作为抗小鼠结核病的新型化疗药物。
FEMS Microbiol Lett. 2006 Aug;261(2):181-6. doi: 10.1111/j.1574-6968.2006.00350.x.
7
Nonclinical models for antituberculosis drug development: a landscape analysis.抗结核药物研发的非临床模型：一项全景分析。
J Infect Dis. 2015 Jun 15;211 Suppl 3:S83-95. doi: 10.1093/infdis/jiv183.
8
Drug resistance in tuberculosis.结核病中的耐药性。
J Chemother. 1990 Jun;2(3):147-51. doi: 10.1080/1120009x.1990.11739007.
9
Trench warfare in a battle with TB.与结核病斗争中的堑壕战。
Science. 2008 Jul 18;321(5887):362-4. doi: 10.1126/science.321.5887.362.
10
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.结核中空纤维模型与结核患者治疗事件的相关性：学习与确认。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S18-24. doi: 10.1093/cid/civ426.

引用本文的文献

1
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant in the hollow fiber system model.奥马环素的药代动力学/药效学及在中空纤维系统模型中对多重耐药菌的疗效。
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0108023. doi: 10.1128/aac.01080-23. Epub 2023 Dec 22.
2
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.应用蒙特卡罗实验确定德拉马尼的药代动力学/药效学敏感性折点。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0140122. doi: 10.1128/aac.01401-22. Epub 2023 Mar 6.
3
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
中空纤维系统模型可重现结核病，并且对药物和联合疗法开发的最佳实践制定了性能规格。
J Antimicrob Chemother. 2023 Apr 3;78(4):953-964. doi: 10.1093/jac/dkad029.
4
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of , methodologies and human studies.抗结核药物的药代动力学和药效学：方法学与人体研究评估
Front Pharmacol. 2022 Dec 9;13:1063453. doi: 10.3389/fphar.2022.1063453. eCollection 2022.
5
Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating .替加环素、法罗培南与莫西沙星联合使用对非复制型结核菌具有潜在活性。 （备注：原文中“Nonreplicating”后面应该少了“mycobacteria”之类的词，根据语境补充完整翻译更通顺，以上是按照补充后完整意思的翻译。）
Front Pharmacol. 2021 Jan 19;11:616294. doi: 10.3389/fphar.2020.616294. eCollection 2020.
6
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.每日一次和每日两次德拉马尼治疗耐多药肺结核患者的应答累积比例。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01207-20.
7
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.乙胺丁醇药代动力学/药效学衍生剂量、MIC 在临床结局中的作用以及耐多药结核病中的耐药时间箭头。
Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.
8
Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.苄青霉素在结核病中的抗菌和消毒作用。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02232-17. Print 2018 Feb.
9
Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.头孢他啶-阿维巴坦对高度耐药结核病具有强大的杀菌活性。
Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.
10
The Role of Public-Private Partnerships in Catalyzing the Critical Path.公私伙伴关系在推动关键路径方面的作用。
Clin Transl Sci. 2017 Nov;10(6):431-442. doi: 10.1111/cts.12488. Epub 2017 Aug 3.